Development of novel small molecule EPHB3 inhibitors to treat neurodegenerative disease by targeting astrocyte‐mediated disease mechanisms

VT-001 emerged as a potent and selective small molecule EPHB3 inhibitor that displays striking in vivo efficacy in neuroinflammation and neurodegeneration disease models. EPHB3 inhibitors in general and VT-001 specifically, represent a highly promising opportunity for novel neurodegenerative disease therapeutics targeting astrocyte-mediated disease mechanisms.